HABA Laboratories, Inc. (4925) Stock Statistics & Valuation Metrics

HABA Laboratories, Inc. has a market cap or net worth of ¥6.23B. The enterprise value is ¥3.31B.

HABA Laboratories, Inc. has 3,935,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

HABA Laboratories, Inc.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.96%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, HABA Laboratories, Inc. had revenue of 12.06B and earned 576.57M in profits. Earnings per share was 152.47.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

HABA Laboratories, Inc. pays an annual dividend of ¥40, resulting in a dividend yield of 2.43%

HABA Laboratories, Inc. upcoming earnings date is Aug 14, 2025, TBA (Confirmed).

HABA Laboratories, Inc. as a current ratio of 3.40, with Debt / Equity ratio of 20.35%

In the past 12 months, HABA Laboratories, Inc. has paid 59.18M in taxes.

HABA Laboratories, Inc. EV to EBITDA ratio is 4.50, with an EV/FCF ratio of 2.46.

HABA Laboratories, Inc. has ¥4.01B in cash and marketable securities with ¥2.11B in debt, giving a net cash position of -¥1.90B billion.

Gross margin is 67.08%, with operating margin of 4.89%, and net profit margin of 4.78%.

The average price target for HABA Laboratories, Inc. is ¥1,815.00, which is 11.43% higher than the current price. The consensus rating is Hold